WSGR logoWSGR logo
Cathy Doxsee
Senior Counsel
Corporate
Palo Alto

D650-849-3308

Download vCard
Open PDF

Catherine (Cathy) Doxsee is senior counsel at Wilson Sonsini Goodrich & Rosati, where her practice focuses on corporate and securities transactions in the technology and life sciences sectors. Cathy works with public and private companies through all stages of their growth, as well as with investment banks and venture capital firms. She regularly works with issuers and underwriters in connection with initial public offerings and other complex capital markets transactions. She also counsels clients on matters such as SEC compliance, disclosure, and corporate governance matters.

From 2007 to 2014, Cathy was an associate in Wilson Sonsini's Palo Alto office. Prior to rejoining the firm, Cathy was counsel in the Menlo Park office of Goodwin Procter LLP.

Experience

Catherine (Cathy) Doxsee is senior counsel at Wilson Sonsini Goodrich & Rosati, where her practice focuses on corporate and securities transactions in the technology and life sciences sectors. Cathy works with public and private companies through all stages of their growth, as well as with investment banks and venture capital firms. She regularly works with issuers and underwriters in connection with initial public offerings and other complex capital markets transactions. She also counsels clients on matters such as SEC compliance, disclosure, and corporate governance matters.

From 2007 to 2014, Cathy was an associate in Wilson Sonsini's Palo Alto office. Prior to rejoining the firm, Cathy was counsel in the Menlo Park office of Goodwin Procter LLP.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Denali Therapeutics on $200 Million Public Offering
On December 10, 2025, Denali Therapeutics, a biopharmaceutical company focused on therapies for neurodegenerative and lysosomal storage diseases, announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. Denali Therapeutics expects to receive total gross proceeds of approximately $200 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the transaction.
Learn More
Client Highlights
Firm Advises Check Point on $2 Billion Convertible Senior Notes Offering
On December 8, 2025, Check Point Software Technologies Ltd. completed an upsized offering of $2 billion aggregate principal amount of convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Check Point had granted to the initial purchasers to purchase up to an additional $250 million of notes. In connection with the offering, Check Point entered into privately negotiated capped call transactions with an affiliate of one of the initial purchasers and certain other financial institutions.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.